neovascular age-related macular degeneration: Natural History and Treatment Outcomes
- PMID: 16340538
- DOI: 10.1097/00006982-200512000-00016
neovascular age-related macular degeneration: Natural History and Treatment Outcomes
Abstract
Background: This review summarizes the data reported in peer-reviewed literature and presents current knowledge on differentiation, natural history, and therapeutic outcomes of neovascular age-related macular degeneration (AMD).
Methods: The MEDLINE database was searched to review natural history of neovascular AMD and therapeutic effects of available treatments.
Results: The search produced>7,000 articles. Research suggests that fluorescein angiographic characterization of location, composition, and size of neovascular lesions may be important in prognosis and should be considered for evaluation of treatment benefits in conjunction with evidence of recent disease progression for lesions not composed of predominantly classic choroidal neovascularization (CNV). Laser photocoagulation, photodynamic therapy with verteporfin, and administration of pegaptanib sodium reduce the risk of vision loss in selected cases of neovascular AMD, while submacular surgery can reduce the risk of severe visual acuity loss in selected cases of predominantly hemorrhagic CNV; further approaches are under investigation.
Conclusion: Visual prognosis of neovascular AMD is variable according to lesion location, composition, and size. Often, lesions have a poor prognosis, resulting in rapid and progressive loss of visual acuity and contrast sensitivity. Such losses have a profound effect on patients' quality of life and ability to perform everyday tasks. Reducing the risk of further loss of visual acuity and contrast sensitivity might enable patients with neovascular AMD to maintain better functional abilities.
Similar articles
-
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.Arch Ophthalmol. 2002 Nov;120(11):1443-54. doi: 10.1001/archopht.120.11.1443. Arch Ophthalmol. 2002. PMID: 12427056 Clinical Trial.
-
Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.Arch Ophthalmol. 2006 May;124(5):660-4. doi: 10.1001/archopht.124.5.660. Arch Ophthalmol. 2006. PMID: 16682587
-
Evolving European guidance on the medical management of neovascular age related macular degeneration.Br J Ophthalmol. 2006 Sep;90(9):1188-96. doi: 10.1136/bjo.2005.082255. Br J Ophthalmol. 2006. PMID: 16929063 Free PMC article.
-
Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.Retina. 2005 Feb-Mar;25(2):119-34. doi: 10.1097/00006982-200502000-00002. Retina. 2005. PMID: 15689800 Review.
-
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.Am J Ophthalmol. 2001 May;131(5):541-60. doi: 10.1016/s0002-9394(01)00967-9. Am J Ophthalmol. 2001. PMID: 11336929 Clinical Trial.
Cited by
-
Molecular mechanisms of subretinal fibrosis in age-related macular degeneration.Exp Eye Res. 2016 Jan;142:19-25. doi: 10.1016/j.exer.2015.03.009. Epub 2015 Mar 13. Exp Eye Res. 2016. PMID: 25773985 Free PMC article. Review.
-
The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD.Invest Ophthalmol Vis Sci. 2022 Jun 1;63(6):17. doi: 10.1167/iovs.63.6.17. Invest Ophthalmol Vis Sci. 2022. PMID: 35713892 Free PMC article.
-
Early neovascular bridging of choroidal neovascularization after ranibizumab treatment.Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1427-30. doi: 10.1007/s00417-009-1143-1. Epub 2009 Jul 21. Graefes Arch Clin Exp Ophthalmol. 2009. PMID: 19621235
-
Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration.Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):645-52. doi: 10.1007/s00417-010-1588-2. Epub 2010 Dec 18. Graefes Arch Clin Exp Ophthalmol. 2011. PMID: 21170547 Free PMC article.
-
Progression from Type 2 Macular Neovascularization to Fibrovascular Pigment Epithelial Detachment.Vision (Basel). 2021 Mar 25;5(2):16. doi: 10.3390/vision5020016. Vision (Basel). 2021. PMID: 33805868 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical